Ischemia-modified albumin: Is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice?

Jin Sun Kim, Hye Jin Hwang, Young Guk Ko, Jung Sun Kim, Donghoon Choi, Jong Won Ha, Myeong Ki Hong, Yangsoo Jang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: We investigated whether ischemia-modified albumin (IMA), a novel biomarker of acute myocardial ischemia, is reliable for diagnosing ischemic chest pain and predicting future cardiac events in clinical practice. Methods: We enrolled 390 patients (age 61.7 ± 39.9 years) who arrived at the emergency department within 6 h of pain onset. We compared serum IMA levels of patients with ischemic chest pain (ICP) to those with nonischemic chest pain (NICP). Results: NICP was diagnosed in 162 patients and ICP in 205 patients. Median serum IMA levels did not differ between the NICP (99.0 U/ml; 95% confidence interval, 98.2-101.2 U/ml) and the ICP group (99.0 U/ml; 95% confidence interval, 99.4-102.6 U/ml; p = 0.320). During a 2-year follow-up, adverse cardiac events including cardiac death, myocardial infarction and recurrent angina occurred in 25 of 205 patients (12.2%) in the ICP group, but IMA was not predictive of cardiac events. Conclusions: IMA was neither able to discriminate acute chest pain due to myocardial ischemia from that of other origin nor to predict cardiac events. Therefore, use of serum IMA levels for triage of patients with acute chest pain does not seem effective in clinical practice.

Original languageEnglish
Pages (from-to)123-129
Number of pages7
JournalCardiology
Volume116
Issue number2
DOIs
Publication statusPublished - 2010 Jul 1

Fingerprint

Chest Pain
Myocardial Ischemia
Acute Pain
ischemia-modified albumin
Confidence Intervals
Triage
Hospital Emergency Service
Biomarkers
Myocardial Infarction
Pain

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

@article{3fd1c08505bf48e7b6f3bb0aceac867e,
title = "Ischemia-modified albumin: Is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice?",
abstract = "Objectives: We investigated whether ischemia-modified albumin (IMA), a novel biomarker of acute myocardial ischemia, is reliable for diagnosing ischemic chest pain and predicting future cardiac events in clinical practice. Methods: We enrolled 390 patients (age 61.7 ± 39.9 years) who arrived at the emergency department within 6 h of pain onset. We compared serum IMA levels of patients with ischemic chest pain (ICP) to those with nonischemic chest pain (NICP). Results: NICP was diagnosed in 162 patients and ICP in 205 patients. Median serum IMA levels did not differ between the NICP (99.0 U/ml; 95{\%} confidence interval, 98.2-101.2 U/ml) and the ICP group (99.0 U/ml; 95{\%} confidence interval, 99.4-102.6 U/ml; p = 0.320). During a 2-year follow-up, adverse cardiac events including cardiac death, myocardial infarction and recurrent angina occurred in 25 of 205 patients (12.2{\%}) in the ICP group, but IMA was not predictive of cardiac events. Conclusions: IMA was neither able to discriminate acute chest pain due to myocardial ischemia from that of other origin nor to predict cardiac events. Therefore, use of serum IMA levels for triage of patients with acute chest pain does not seem effective in clinical practice.",
author = "Kim, {Jin Sun} and Hwang, {Hye Jin} and Ko, {Young Guk} and Kim, {Jung Sun} and Donghoon Choi and Ha, {Jong Won} and Hong, {Myeong Ki} and Yangsoo Jang",
year = "2010",
month = "7",
day = "1",
doi = "10.1159/000317091",
language = "English",
volume = "116",
pages = "123--129",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "2",

}

Ischemia-modified albumin : Is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice? / Kim, Jin Sun; Hwang, Hye Jin; Ko, Young Guk; Kim, Jung Sun; Choi, Donghoon; Ha, Jong Won; Hong, Myeong Ki; Jang, Yangsoo.

In: Cardiology, Vol. 116, No. 2, 01.07.2010, p. 123-129.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ischemia-modified albumin

T2 - Is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice?

AU - Kim, Jin Sun

AU - Hwang, Hye Jin

AU - Ko, Young Guk

AU - Kim, Jung Sun

AU - Choi, Donghoon

AU - Ha, Jong Won

AU - Hong, Myeong Ki

AU - Jang, Yangsoo

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objectives: We investigated whether ischemia-modified albumin (IMA), a novel biomarker of acute myocardial ischemia, is reliable for diagnosing ischemic chest pain and predicting future cardiac events in clinical practice. Methods: We enrolled 390 patients (age 61.7 ± 39.9 years) who arrived at the emergency department within 6 h of pain onset. We compared serum IMA levels of patients with ischemic chest pain (ICP) to those with nonischemic chest pain (NICP). Results: NICP was diagnosed in 162 patients and ICP in 205 patients. Median serum IMA levels did not differ between the NICP (99.0 U/ml; 95% confidence interval, 98.2-101.2 U/ml) and the ICP group (99.0 U/ml; 95% confidence interval, 99.4-102.6 U/ml; p = 0.320). During a 2-year follow-up, adverse cardiac events including cardiac death, myocardial infarction and recurrent angina occurred in 25 of 205 patients (12.2%) in the ICP group, but IMA was not predictive of cardiac events. Conclusions: IMA was neither able to discriminate acute chest pain due to myocardial ischemia from that of other origin nor to predict cardiac events. Therefore, use of serum IMA levels for triage of patients with acute chest pain does not seem effective in clinical practice.

AB - Objectives: We investigated whether ischemia-modified albumin (IMA), a novel biomarker of acute myocardial ischemia, is reliable for diagnosing ischemic chest pain and predicting future cardiac events in clinical practice. Methods: We enrolled 390 patients (age 61.7 ± 39.9 years) who arrived at the emergency department within 6 h of pain onset. We compared serum IMA levels of patients with ischemic chest pain (ICP) to those with nonischemic chest pain (NICP). Results: NICP was diagnosed in 162 patients and ICP in 205 patients. Median serum IMA levels did not differ between the NICP (99.0 U/ml; 95% confidence interval, 98.2-101.2 U/ml) and the ICP group (99.0 U/ml; 95% confidence interval, 99.4-102.6 U/ml; p = 0.320). During a 2-year follow-up, adverse cardiac events including cardiac death, myocardial infarction and recurrent angina occurred in 25 of 205 patients (12.2%) in the ICP group, but IMA was not predictive of cardiac events. Conclusions: IMA was neither able to discriminate acute chest pain due to myocardial ischemia from that of other origin nor to predict cardiac events. Therefore, use of serum IMA levels for triage of patients with acute chest pain does not seem effective in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=77953945464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953945464&partnerID=8YFLogxK

U2 - 10.1159/000317091

DO - 10.1159/000317091

M3 - Article

C2 - 20588021

AN - SCOPUS:77953945464

VL - 116

SP - 123

EP - 129

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 2

ER -